Skip to main content
Top
Published in: Clinical and Translational Oncology 6/2016

01-06-2016 | Research Article

Concurrent chemo-radiotherapy in elderly patients: tolerance and compliance in a series of 137 patients

Authors: M. Di Genesio Pagliuca, C. Perotti, G. Apicella, A. Galla, M. Guffi, M. Paolini, L. Donis, V. Amisano, S. Torrente, I. Manfredda, M. Krengli

Published in: Clinical and Translational Oncology | Issue 6/2016

Login to get access

Abstract

Introduction

Aggressive cancer treatment is a challenge in elderly patients. The present study aims to assess tolerance in terms of acute toxicity and compliance of concurrent chemo-radiotherapy (cCRT) in a series of patients aged ≥70 years.

Materials and methods

Clinical records of patients aged ≥70 years who underwent cCRT between January 2005 and December 2013 were reviewed. Concurrent CRT had curative intent in 134 patients (97.8 %) and palliative intent in 3 patients (2.2 %). Chemotherapy (CT) drugs and schedule were selected according to tumor histology. Radiotherapy median dose was 45.0 Gy (range 11–70 Gy) for curative purposes and 54 Gy (range 40–56 Gy) for palliative purposes. Incidence of acute toxicity and compliance to cCRT were analyzed and correlated with age, Karnofsky Performance Status (KPS), and Charlson Comorbidity Index (CCI).

Results

Overall, 137 patients, 82 males (60 %) and 55 females (40 %), median age 74 years (range 70–90 years) were analyzed. Concurrent CRT schedule was completed by 132 patients (96.4 %). Thirty-one of these patients (23.5 %) temporarily interrupted treatment. Hematological toxicity with grade ≥1 was observed in 25 patients (18.2 %), gastrointestinal toxicity in 55 (40.1 %), and genitourinary in 13 (9.5 %). Mucositis with grade ≥1 was recorded in 19 patients (13.9 %). No statistical significant correlation between KPS, CCI, and toxicity was found. A correlation trend between mucositis and patient age (p = 0.05) was observed.

Conclusion

Concurrent CRT for elderly was feasible and quite well tolerated. Great attention in prescribing CT dose should be paid to limit acute toxicity.
Literature
1.
go back to reference Yancik R, Ries LA. Cancer in older persons: an international issue in an aging world. Semin Oncol. 2004;31:128–36.CrossRefPubMed Yancik R, Ries LA. Cancer in older persons: an international issue in an aging world. Semin Oncol. 2004;31:128–36.CrossRefPubMed
2.
go back to reference Nguyen TD, Azria D, Brochon D, Poortmans P, Miller RC, Scandolaro L, et al. Curative external beam radiotherapy in patients over 80 years of age with localized prostate cancer: a retrospective rare cancer network study. Crit Rev Oncol Hematol. 2010;74:66–71.CrossRefPubMed Nguyen TD, Azria D, Brochon D, Poortmans P, Miller RC, Scandolaro L, et al. Curative external beam radiotherapy in patients over 80 years of age with localized prostate cancer: a retrospective rare cancer network study. Crit Rev Oncol Hematol. 2010;74:66–71.CrossRefPubMed
4.
5.
6.
go back to reference Pallis AG, Fortpied C, Wedding U, Van Nes MC, Penninckx B, Ring A, et al. EORTC elderly task force position paper: approach to the older cancer patient. Eur J Cancer. 2010;46:1502–13.CrossRefPubMed Pallis AG, Fortpied C, Wedding U, Van Nes MC, Penninckx B, Ring A, et al. EORTC elderly task force position paper: approach to the older cancer patient. Eur J Cancer. 2010;46:1502–13.CrossRefPubMed
7.
go back to reference Lewis JH, Kilgore ML, Goldman DP, Trimble EL, Kaplan R, Montello MJ, et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol. 2003;21:1383–9.CrossRefPubMed Lewis JH, Kilgore ML, Goldman DP, Trimble EL, Kaplan R, Montello MJ, et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol. 2003;21:1383–9.CrossRefPubMed
8.
9.
go back to reference Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol. 2004;22:4626–31.CrossRefPubMed Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol. 2004;22:4626–31.CrossRefPubMed
10.
go back to reference Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999;341:2061–7.CrossRefPubMed Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999;341:2061–7.CrossRefPubMed
11.
go back to reference Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol. 1984;2:187–93.PubMed Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol. 1984;2:187–93.PubMed
12.
go back to reference Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–55.CrossRefPubMed Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–55.CrossRefPubMed
13.
go back to reference Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.CrossRefPubMed Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.CrossRefPubMed
15.
go back to reference Papamichael D, Audisio R, Horiot JC. Treatment of the elderly colorectal cancer patient: SIOG expert recommendations. Ann Oncol. 2009;20:5–16.CrossRefPubMed Papamichael D, Audisio R, Horiot JC. Treatment of the elderly colorectal cancer patient: SIOG expert recommendations. Ann Oncol. 2009;20:5–16.CrossRefPubMed
17.
go back to reference Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2004;291:2441–7.CrossRefPubMed Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2004;291:2441–7.CrossRefPubMed
18.
go back to reference Lichtman SM, Wildiers H, Chatelut E, Steer C, Budman D, Morrison VA, et al. International Society of Geriatric Oncology Chemotherapy Taskforce. International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients—an analysis of the medical literature. J Clin Oncol. 2007;25:1832–43.CrossRefPubMed Lichtman SM, Wildiers H, Chatelut E, Steer C, Budman D, Morrison VA, et al. International Society of Geriatric Oncology Chemotherapy Taskforce. International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients—an analysis of the medical literature. J Clin Oncol. 2007;25:1832–43.CrossRefPubMed
19.
go back to reference Pasetto LM, Friso ML, Pucciarelli S, Basso U, Falci C, Bortolami A, et al. Rectal cancer neoadjuvant treatment in elderly patients. Anticancer Res. 2006;26:3913–23.PubMed Pasetto LM, Friso ML, Pucciarelli S, Basso U, Falci C, Bortolami A, et al. Rectal cancer neoadjuvant treatment in elderly patients. Anticancer Res. 2006;26:3913–23.PubMed
20.
go back to reference Margalit DN, Mamon HJ, Ancukiewicz M, Kobayashi W, Ryan DP, Blaszkowsky LS, et al. Tolerability of combined modality therapy for rectal cancer in elderly patients aged 75 years and older. Int J Radiat Oncol Biol Phys. 2011;81:e735–41.CrossRefPubMed Margalit DN, Mamon HJ, Ancukiewicz M, Kobayashi W, Ryan DP, Blaszkowsky LS, et al. Tolerability of combined modality therapy for rectal cancer in elderly patients aged 75 years and older. Int J Radiat Oncol Biol Phys. 2011;81:e735–41.CrossRefPubMed
21.
go back to reference Michal SA, Adelstein DJ, Rybicki LA, Rodriguez CP, Saxton JP, Wood BG, et al. Multi-agent concurrent chemoradiotherapy for locally advanced head and neck squamous cell cancer in the elderly. Head Neck. 2012;34:1147–52.CrossRefPubMed Michal SA, Adelstein DJ, Rybicki LA, Rodriguez CP, Saxton JP, Wood BG, et al. Multi-agent concurrent chemoradiotherapy for locally advanced head and neck squamous cell cancer in the elderly. Head Neck. 2012;34:1147–52.CrossRefPubMed
22.
go back to reference Pignon JP, le Maître A, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92:4–14.CrossRefPubMed Pignon JP, le Maître A, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92:4–14.CrossRefPubMed
23.
go back to reference Kodaira T, Fuwa N, Furutani K, Tachibana H, Yamazaki T. Phase I trial of weekly docetaxel and concurrent radiotherapy for head and neck cancer in elderly patients or patients with complications. Jpn J Clin Oncol. 2005;35:173–6.CrossRefPubMed Kodaira T, Fuwa N, Furutani K, Tachibana H, Yamazaki T. Phase I trial of weekly docetaxel and concurrent radiotherapy for head and neck cancer in elderly patients or patients with complications. Jpn J Clin Oncol. 2005;35:173–6.CrossRefPubMed
24.
go back to reference Wasil T, Lichtman SM, Gupta V, Rush S. Radiation therapy in cancer patients 80 years of age and older. Am J Clin Oncol. 2000;23:526–30.CrossRefPubMed Wasil T, Lichtman SM, Gupta V, Rush S. Radiation therapy in cancer patients 80 years of age and older. Am J Clin Oncol. 2000;23:526–30.CrossRefPubMed
25.
go back to reference Nguyen NP, Vock J, Chi A, Vinh-Hung V, Dutta S, Ewell L, et al. Impact of intensity-modulated and image guided radiotherapy on elderly patients undergoing chemoradiation for locally advanced head and neck cancer. Strahlenther Onkol. 2012;188:677–83.CrossRefPubMed Nguyen NP, Vock J, Chi A, Vinh-Hung V, Dutta S, Ewell L, et al. Impact of intensity-modulated and image guided radiotherapy on elderly patients undergoing chemoradiation for locally advanced head and neck cancer. Strahlenther Onkol. 2012;188:677–83.CrossRefPubMed
26.
go back to reference Tougeron D, Hamidou H, Scotté M, Di Fiore F, Antonietti M, Paillot B, et al. Esophageal cancer in the elderly: an analysis of the factors associated with treatment decisions and outcomes. BMC Cancer. 2010;10:510.CrossRefPubMedPubMedCentral Tougeron D, Hamidou H, Scotté M, Di Fiore F, Antonietti M, Paillot B, et al. Esophageal cancer in the elderly: an analysis of the factors associated with treatment decisions and outcomes. BMC Cancer. 2010;10:510.CrossRefPubMedPubMedCentral
27.
go back to reference Lu X, Wu H, Wang J, Xu J. Short- and long-term outcomes of definitive chemoradiotherapy in patients with esophageal carcinoma aged ≥ 75 years. Mol Clin Oncol. 2014;2:297–301.PubMedPubMedCentral Lu X, Wu H, Wang J, Xu J. Short- and long-term outcomes of definitive chemoradiotherapy in patients with esophageal carcinoma aged ≥ 75 years. Mol Clin Oncol. 2014;2:297–301.PubMedPubMedCentral
28.
go back to reference Gzell C, Wheeler H, Guo L, Kastelan M, Back M. Elderly patients aged 65–75 years with glioblastoma multiforme may benefit from long course radiation therapy with temozolomide. J Neurooncol. 2014;119:187–96.CrossRefPubMed Gzell C, Wheeler H, Guo L, Kastelan M, Back M. Elderly patients aged 65–75 years with glioblastoma multiforme may benefit from long course radiation therapy with temozolomide. J Neurooncol. 2014;119:187–96.CrossRefPubMed
29.
go back to reference Lanzetta G, Minniti G. Treatment of glioblastoma in elderly patients: an overview of current treatments and future perspective. Tumori. 2010;96:650–8.PubMed Lanzetta G, Minniti G. Treatment of glioblastoma in elderly patients: an overview of current treatments and future perspective. Tumori. 2010;96:650–8.PubMed
Metadata
Title
Concurrent chemo-radiotherapy in elderly patients: tolerance and compliance in a series of 137 patients
Authors
M. Di Genesio Pagliuca
C. Perotti
G. Apicella
A. Galla
M. Guffi
M. Paolini
L. Donis
V. Amisano
S. Torrente
I. Manfredda
M. Krengli
Publication date
01-06-2016
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 6/2016
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-015-1403-y

Other articles of this Issue 6/2016

Clinical and Translational Oncology 6/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine